Last reviewed · How we verify
Tenofovir intravaginal ring
At a glance
| Generic name | Tenofovir intravaginal ring |
|---|---|
| Also known as | Tenofovir disoproxil fumarate intravaginal ring, TFV IVR |
| Sponsor | CONRAD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir (PHASE1)
- PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study) (EARLY_PHASE1)
- Tenofovir/Levonorgestrel Intravaginal Ring and Tenofovir Intravaginal Ring (PHASE2)
- The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples (SAFER)
- Safety, PK, and PD Study of IVRs Releasing TFV and LNG (PHASE1)
- Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (PHASE1)
- Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002) (PHASE1)
- Exploratory Pharmacodynamic Study of Tenofovir-Based Products (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |